August 8, 2025 — BiotechReporter.news — BioVie Inc. (NASDAQ: BIVI, BIVIW) announced the pricing of its underwritten public offering of 6,000,000 units, each consisting of one share of common stock and one warrant. The offering is expected to generate gross proceeds of approximately $12 million before deductions.
Each unit is priced at $2.00, while pre-funded units are sold at a price less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant. The warrants have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BIVIW” on August 8, 2025.
The company has granted the underwriter a 45-day option to purchase additional shares, pre-funded warrants and/or warrants to cover over-allotments.
BioVie intends to use the proceeds for working capital and general corporate purposes. The offering is expected to close on August 11, 2025, subject to customary closing conditions. ThinkEquity is acting as sole book-running manager for the offering.
Chuck Padala, Managing Director, Investor Relations, chuck@lifesciadvisors.com; Melyssa Weible, Managing Partner, Elixir Health Public Relations, mweible@elixirhealthpr.com
Source: BioVie Inc.
